Skip to main content

Original publications

Original publications including review articles, presented by publiction year.

2018

  1. Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinson G, Jungner I, Van Hemelrijck M. Serum glucose, triglycerides and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes & Control. Cancer Causes Control. 2018 Epub ahead of print. PMID: 30421156
  2. Ghoshal A, Garmo H, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Van Hemelrijck M. Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival? BMC Cancer. 2018;18:1169. PMID: 30477464.
  3. Ivert T, Malmström H, Hammar N, Carlsson AC, Wändell PE, Holzmann MJ, Jungner I, Ärnlöv J, Walldius G. Cardiovascular events before 50 years of age – metabolic risk factors are elevated since more than 20 years. Plos Medicine. In review.
  4. Malmström H, Walldius G, Carlsson S, Grill V, Jungner I, Gudbjörnsdottir S, Kosiborod M, Hammar N. Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes – experience from the AMORIS study. Diabetes Obesity Metabolism 2018. [Epub ahead of print]. PMID: 29400911
  5. Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Van Hemelrijck M. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. Int J Cancer 2018 [Epub ahead of print]. PMID: 29322512.
  6. Bosco C, Garmo H, Hammar N, Walldius G, Jungner I, Malmström H, Holmberg L, Van Hemelrijck M. Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumors: a prospective study in the Swedish AMORIS cohort. BMC Cancer. 2018;18(1):205. PMID: 29463235

2017

  1. Walldius G, Malmström H, de Faire U, Jungner I, Lambe M, van Hemelrijk M, Hammar N. The AMORIS cohort. Int J Epidemiol. 2017; 46:1-10. PMID: 28158674.
  2. Rowley M, van Hemelrijck M. Wulaningsih, W, Grundmark B, Zethelius B, Hammar N, Walldius G, Masato I, Holmberg L, Coolen T. A latent class model for competing risks. Stati Med 2017. Epub ahead of print. PMID: 28233395
  3. Shackshaft L, Van Hemelrijck M, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W. Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort. Breast Cancer Res. 2017;19:22. PMID: 28264697.
  4. Yiu A, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget. 2017. Epub ahead of print. PMID: 28418841.
  5. Mariosa D, Hammar N, Malmström H, Ingre C, Jungner I, Lambe M, Ye W, Fang F, Walldius G. Blood biomarkers of carbohydrate, lipid and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20 year follow-up of the Swedish AMORIS cohort. Annals of Neurology 2017. Epub ahead of print. PMID: 28437840.
  6. Schwartzbaum J, Edlinger M, Zigmont V, Stattin P, Rempala GA, Nagel G, Hammar N, Ulmer H, Föger B, Walldius G, Manjer J, Malmström H, Feychting M. Associations between prediagnostic blood glucose levels, diabetes and glioma. Sci Rep 2017;7: 1436. PMID: 28469238
  7. Melvin JC, Garmo H, Holmberg L, Hammar N, Walldius G, Jungner I, Lambe M, Van Hemelrijck M. Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort. BMC Cancer 2017;17:246.PMID: 28376727
  8. Nderitu P, Bosco C, Garmo H, Holmberg L, Malmström H, Hammar N, Walldius G, Jungner I, Lambe M, Ross P, Van Hemelrijck M. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort. Int J Cancer. 2017;141:1148-1160. PMID: 28577304.
  9. Ghoshal A, Garmo H, Arthur R, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Van Hemelrijck M. Serum biomarkers to predict risk of testicular and penile cancer in AMORIS. Ecancermedicalscience. 2017;11:762. PMID:28900475.
  10. Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, Adolfsson J, Stattin P, Van Hemelrijck M. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists. BJU Int. 2017. [Epub ahead of print], PMID: 28940667
  11. Ghosal A, Garmo H, Arthur R, Carroll P, Holmberg L, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Van Hemelrijck M. Thyroid cancer risk in the Swedish AMORIS study: The role of inflammatory biomarkers in serum. Oncotarget. 2017;9:774-782.PMID: 2941665.

2016

  1. Holzmann MJ, Carlsson AC, Hammar N, Ivert T, Walldius G, Wändell P, Ärnlöv J. Chronic kidney disease and 10-year risk of cardiovascular death. Eur J Prev Cardiol. 2016 23:1187-94. PMID: 26541858.
  2. Rohrmann S, Garmo H, Malmström H, Hammar N, Jungner I, Walldius G, Van Hemelrijck M. Association between serum calcium concentration and risk of incident and fatal heart disease in the prospective AMORIS study. Atherosclerosis. 2016; 251:85-93. PMID:27289190.
  3. Bernardo BM, Orellana RC, Weisband YL, Hammar N, Walldius G, Malmstrom H, Ahlbom A, Feychting M, Schwartzbaum J. Association between prediagnostic glucose, triglycerides, cholesterol and meningioma and reverse causation. Br J Cancer. 2016; 115(1):108-14. PMID:27253176.
  4. Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Hemelrijck MV. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016; 6:1307-18. PMID:26923095.
  5. Malmström H, Wändell PE, Holzmann M, Ärnlöv J, Walldius G, Hammar N, Jungner I, Carlsson AC. Low fructosamine levels and mortality – a 25-year follow-up of 251,621 Swedish non-diabetic subjects. Nutr Metab Cardiovasc Dis. 2016 [Epub ahead of print]. PMID:27751668.
  6. Wulaningsih W, Sagoo HK, Hamza M, Melvin J, Holmberg L, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Van Hemelrijck M. Serum calcium and the risk of breast cancer. Findings from the Swedish AMORIS Study and meta-analysis of prospective studies. Int J Mol Sci. 2016 ;6;17(9).PMID:27608013.
  7. Wulaningsih W, Holmberg L, Garmo H, Karagiannis SN, Ahlstedt S, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M. Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. Oncoimmunology. 2016; 28;5:e1154250. PMID:27471625.

2015

  1. Wulaningsih W, Holmberg L, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis. 2015; 36:1121-8. PMID: 26130675.
  2. Malmström H, Walldius G, Grill V, Jungner I, Hammar N. Fructosamine is a risk factor for myocardial infarction and all-cause mortality – longitudinal experience from the AMORIS cohort. Nutr Metab Cardiovasc Dis. 2015;25:943-50. PMID: 26296867.
  3. Wulaningsih W, Holmberg L, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M. Serum lacatate dehydrogenase and survival following cancer diagnosis. Br J Cancer. 2015; 113:1389-96. PMID: 26469834.
  4. Wulaningsih W, Vahdaninia M, Rowley M, Holmberg L, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Coolen AC, Van Hemelrijck M. Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer. 2015;15:913. PMID: 26577580.

2014

  1. Wulaningsih W, Garmo H, Holmberg L, Hammar N, Jungner I, Walldius G, Van Hemelrijck M. Serum glucose and lipids in relation to gastrointestinal cancer risk. Clinical Gastroenterology and Hepatology 2014;12(1):159-63.
  2. Malmström H, Walldius G, Grill V, Jungner I, Gudbjörnsdottir S, Hammar N. Fructosamine is a useful indicator of hyperglyceamia and glucose control in clinical and epidemiological studies – cross sectional and longitudinal experience from the AMORIS cohort. PLoS One. 2014;29:e111463. PMID: 25353659.

2013

  1. Wulaningsih W, Holmberg L, Garmo H, Zethelius B, Wigertz A, Carrol P, Lambe M, Hammar N, Walldius G, Jungner I, Van Hemelrijck M. Serum glucose and fructosamine in relation to the risk of cancer. PLoS One 2013;8.e54944. PMID: 23372798.
  2. Carlsson AC, Wändell PE, Hedlund E, Walldius G, Nordqvist T, Jungner I, Hammar N. Country of birth-specific prevalence of diabetes in Sweden. Diabetes Res Clin Pract 2013; http://dx.doi.org/10.1016/j.diabres.2013.03.014
  3. Gaur A, Hammar N, Holmberg L, Jungner I, Collins H, Garmo H, Walldius G, Wulaningsih W, Van Hemelrijck M. Iron metabolism and risk of cancer in the Swedish AMORIS study. Cancer causes & control : CCC 2013;24(7):1393 – 402.
  4. Wulaningsih W, Michaelsson K, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, Holmberg L, Van Hemelrijck M. Inorganic phosphate and the risk of cancer in the Swedish AMORIS study. BMC Cancer. 2013;13:257. Doi: 10.1186/1471-2407-13-257.
  5. Wulaningsih W, Michaelsson K, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, Holmberg L, Van Hemelrijck M. Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study. BMC Public Health 2013;13(1):663 (Epub ahead of print)

2012

  1. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. High blood hemoglobin concentration as risk factor of major atherosclerotic cardiovascular events in 114,159 healthy men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Ann Med, 2012;44(5):476-86.
  2. Melvin J, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, Wigertz A, Van Hemelrijck M. Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiology Biomarkers and Prevention (2012): Published online July 13. Paper published; Cancer Epidemiol, Biomarkers Prev 2012; 21: 1381-4. PMID: 22593241.
  3. Holzmann M, Jungner I, Walldius G, Ivert T, Nordqvist T, Östergren J, Hammar N. Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. Annals of Medicine, 2012; 44: 262-70.
  4. Holzmann MJ, Aastveit A, Hammar N, Jungner I, Walldius G. Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population. Annals of Medicine, 2012;44:607-15.
  5. Van Hemerijck M, Harari D, Garmo H, Hammar N, Walldius G, Lambe M, Jungner I, Holmberg L. Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. Int J Mol Epidemil Genet 2012;3: 66-76. PMID: 22493753.
  6. Van Hemelrijck M, Garmo H, Hammar N, Jungner I, Walldius G, Lambe H, Holmberg L The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. Int J Cancer 2012;130(9):2118-28.
  7. Van Hemerijck M, Hermans R, Michaelsson K, Melvin J, Garmo H, Hammar N, Jungner I, Walldius G, Holmberg L. Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer causes and Control 2012;23:1349-58. PMID: 22710746.
  8. Seth D, Garmo H, Wigertz A, Holmberg L, Hammar N, Jungner I, Lambe M, Walldius G, Van Hemelreijck. Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. Int J Mol Epidemiol Genet 2012;3:122-33. PMID: 22724049.
  9. Melvin JC, Rodrigues C, Holmberg L, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, Jassem W, Van Hemelrijck M. Gamma-glutamyl transferas and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidities: a prospective study. Int J Mol Epidemiol Genet 2012;3:276-85. PMID: 23205179.
  10. Wulaningsih W, Walldius G, Garmo H, Hammar N, Holmberg L, Jungner I, Van Hemelrijck M. Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. J Cancer Epidemiol. 2012():792034. Epub ahead of print. PMID: 22969802.
  11. Walldius G. The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk, Published in: Lipoproteins in Health and Diseases, ISBN 978-***********-6, eds. Frank S and Kostner G. 2012, pages 95-148. http://dx.doi.org/10.5772/47869.

2011

  1. Van Hemelrijck M, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M, Holmberg L. The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. Int J Cancer 2011;130(9):2118-28.
  2. Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes and Control 2011; 22(7):1011-9.
  3. Van Hemelrijck M, Jassem W, Walldius G, Fentiman IS, Hammar N, Lambe M, Garmo H, Jungner I, Holmberg L. Gamma-glutamyl transferase and risk of cancer in a cohort of 545,460 persons – the Swedish AMORIS study. European Journal of Cancer 2011; 47(13):2033-41.
  4. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, Binda E, Lambe M, Jungner I. Association between levels of C-reactive protein and leukocytes and cancer: Three repeated measurements in the Swedish AMORIS study. Cancer Epidemiology Biomarkers and Prevention 2011;20(3):428-37.
  5. Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, Lambe M. Prostate cancer risk in the Swedish AMORIS study: The interplay among triglycerides, total cholesterol, and glucose. Cancer 2011;117(10):2086-95.

2010

  1. Semb AG, Kvien TK, Aastveit AH, Jungner J, Pedersen TR, Walldius G, Holme I. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis 2010; 69(11):1996-2001.
  2. Holtzmann M, Ivert T, Jungner I, Nordqvist T, Walldius G, Östergren J, Hammar N. Renal function assessed by two different formulas and incidence of myocardial infarction and death in middle-aged men and women. J Intern Med 2010;267:357-69. PMID: 20433582.73.
  3. Holzmann M, Jungner I, Walldius G, Ivert T, Östergren J, Hammar N. Apolipoproteins B and A-I, standard lipid measures and incidence of myocardial infarction in men and women, with or without chronic kidney disease. J Am Soc Nephrol. Part of thesis by Holzmann (paper no IV).
  4. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Atherosclerosis 2010;213:299-305.
  5. Van Hemelrijck M, Jungner I, Walldius G, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L, Hammar N. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer 2010;129(6):1485-92.
  6. Walldius G, Jungner I. Apolipoproteinerna B och A-I kliniskt användbara riskprediktorer – 25 år med AMORIS-studien. Incitament 2010;19;513-31.
  7. Walldius G. Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non-HDL cholesterol and LDL cholesterol. J Intern Med 2010;268(6):549-51.
  8. Van Hemelrijck M, Garmo H, Binda E, Hayday A, Karagiannis SN, Hammar N, Walldius G, Lambe M, Jungner I, Holmbeg L. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes Control 2010 Oct;21(10):1657-67. Epub 2010 June 9.
  9. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial and ovarian cancer. Cancer Causes Control 2011;22:1163-71. PMID: 21688131.
  10. Van Hemelrijck M, Jungner I, Walldius G, Garmo H, Binda E, Hayday A, Lambe M, Holmbeg L, Hammar N. Risk of prostata cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer 2011;129(6):1485-92.

2009

  1. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Haptoglobin and risk of myocardial infarction, stroke and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). I First article 2009; 1-11 then published in Ann Med 2009; 41: 522-33. PMID: 19657769.
  2. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009; 266:558-70. PMID: 19563390.
  3. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Lipoprotein components and risk of congestive heart failure in 84,470 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Eur J Heart Fail 2009;11:1036-42. PMID: 19801574.
  4. Sierra -Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Öhrvik J, Walldius G, Hellenius ML, Hamsten A. The concentration of apolipoprotein B is comparable to the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: Findings from a multiethnic US population. Europ Heart J. 2009; 30:710-7. PMID: PMID: 18676970.
  5. Solphour A, Parkhideh S, Sarrafzadegan N, Asgary S, Williams K, Jungner I, Aastveit A, Walldius G, Sniderman A. Levels of lipids and apolipoproteins in three cultures. Atherosclerosis 2009; 207: 200-7. PMID: PMID: 19766218.
  6. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Relationships between lipoprotein components and risk of ischemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009:265:275-87. PMID: 19019184.
  7. Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2008; 264: 30-8, doi:10.1111/j.1365-2796.2008.01925.x.

2007

  1. Sierra-Johnson Justo, Romero-Corral Abel, Somers Virend K., Lopez-Jimenez Fransisco, Wall­dius Göran, Hamsten Anders, Hellénius Mai-Lis, Fisher Rachel M. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Europ Heart J Advanced Access, published Sept 1, 2007.
  2. Walldius G, Jungner I. ApoB, apoA-I, and the apoB/apoA-I ratio as predictors, markers, and factors for cardiovascular risk. The Fats of Life. www.aacc.org. 2007;XXI, No1:11-21.
  3. Walldius G, Jungner I. Apolipoprotein A-I versus HDL-cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol. 2007;22:359-67.
  4. Walldius G, Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I – new risk factors and targets for therapy. Nutr Metab Cardio­vasc Dis. 2007;17:565-71.
  5. Sniderman AD, Holme I, Aastveit A, Furberg C, Walldius G, Jungner I. Relation of age, the apolipoproteinB/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for primary prevention of cardiovascular disease. Am J Cardiol. 2007;100:217-21.
  6. Walldius G, Holme I, Jungner I. Apolipoproteiner bättre riskmarkörer än konventionella lipi­der. Läkartidningen 2007;104(37):2612-13.

2006

  1. Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G. Does Low-Density Lipoprotein Size Add to Atherogenic Particle Number in Predicting the Risk of Fatal Myocardial Infarction? Amer J Cardiol. 2006;97:943-6.
  2. Walldius G, Aastveit AH, Jungner I. Stroke Mortality and the apoB/apoA-I ratio: Results from the AMORIS Prospective Study. J Internal Med. 2006;259:259-66.
  3. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk for vascular disease. J Intern Med. 2006;259:455-61.
  4. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. [Erratum to document cited in CA145:415475]. J Intern Med. 2006;260(2):186.
  5. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman M, Couture P, deGraaf J,Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humpheries SE, Jungner I, Krauss RM, Kwiterowich P, Marcovina S, Packard CJ, Pearson TA, Readdy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stahlenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KMS. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259:247-58.
  6. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular dis­ease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med. 2006;259:493-519.

2005

  1. Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indica­tors of cardiac risk and as targets for lipid-lowering therapy. Editorial. Europ Heart J 2005;26:210-12.

2004

  1. Walldius G & Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of CHD and targets for lipid-modifying therapy. J Intern Med 2004; 255: 188-205.
  2. Walldius G, Aastveit A & Jungner I. Hypercholesterolemia and hypertriglyceridemia – greatest cardiac risk in subjects with high apoB/apoA-I levels. Internat Atheroscler Soc. 2004; 3; 1262 C; 203-206.
  3. Walldius G, Jungner I. Apolipoproteiner nya och bättre riskindikatorer för hjärtinfarkt. Läkar­tidningen 2004; 101:1188-94.

2003

  1. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. The Lancet 2003; 361: 777-80.
  2. Sniderman AD, Furberg CD, Roeters van Lennep JE, Jungner I, Walldius G. Lipoprotein and cardiovascular risk. Authors’ reply. The Lancet 2003; 361: 1989.
  3. Walldius G, Jungner I. Apolipoproteiner – nya riskmarkörer för kardiovaskulär sjukdom. Medicinskt Forum 2003; 2. Artikeln även publicerad i DiabetologNytt 16(4) 1-8.
  4. Walldius G, Jungner I. Apolipoproteiner – nya riskmarkörer för kardiovaskulär sjukdom. Laboratoriet 2003; 4: 10-13.

2002

  1. Walldius G, Jungner I, Aastveit A, Holme I. Apolipoproteins and prediction of fatal myocar­dial infarction. Authors’ reply. The Lancet 2002; 359:1863-64.

2001

  1. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. The Lancet 2001; 358:2026-33.
  2. Jungner I, Marcovina SM, Walldius G, Holme I, KolarW, Steiner E. Apolipoprotein B and A-I values in 147,576 Swedish males and females, standardized according to the World Health Organization – International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998; 44/8:1641-49.

1992

  1. Jungner I, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-1 in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females. Int J Clin Lab Res 1992, 21: 247 - 55.
  2. Walldius G, Jungner I, Kolar W, Holme I, Steiner E. High cholesterol and triglyceride values in Swedish males and females: Increased risk of fatal myocardial infarction. First Report from the AMORIS (Apolipoprotein related Mortality Risk) Study. Blood Pressure 1992; 1 (Suppl 4): 35 - 42.
  3. Walldius G, Jungner I, Kolar W, Holme I & Steiner E. AMORIS-studien: Höga kolesterol- och triglyceridvärden - hög risk för död i hjärtinfarkt. Symposium, Göteborg. Kardiologi 1992; 3-4: 23 - 26.

1990

  1. Walldius G, Jungner I, Kolar W, Steiner E. Apolipoprotein B and total serum cholesterol levels in 41,000 males and females. Clin Chem 1990; 36/6:952.

1989

  1. Walldius G, Jungner I. Hypertriglyceridemi – en vanlig, ofta förbisedd blodfettrubbning. Läkar­tidningen 1989; 48: 4227-4230.

1987

  1. Walldius G, Jungner I. Lämpligt med två gränsvärden vid diagnostik och behandling av högt serumkolesterol. Läkartidningen 1988; 45:3835-39.